Print Friendly, PDF & Email

NCT/Study#

NCT04050436 /

RPL-002-18

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

DISEASE GROUP:
Skin and Soft Tissue
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: